| | National Drug Threat Assessment - 2005 |
| | 4,41 | | MB |
| | 226 | | stron |
| | 5695 | | ID | National Drug Intelligence Center |
| | 2007 | | rok |
| | Table of Contents |
| | Executive Summary . v |
| | Scope and Methodology . xi |
| | Cocaine.1 |
| | Introduction and Trends . .1 |
| | Availability .2 |
| | Demand . .2 |
| | Production . .3 |
| | Transportation .3 |
| | Distribution .3 |
| | Availability . .4 |
| | Demand.6 |
| | Predominant User Groups . .6 |
| | Trends in Use . .6 |
| | Perceptions of Use . .8 |
| | Trends in Consequences of Use .8 |
| | Production .10 |
| | Transportation.11 |
| | Mexico–Central America Corridor . .12 |
| | Caribbean Corridor . .13 |
| | Direct to the Continental United States .14 |
| | In the United States . .14 |
| | Distribution . .14 |
| | Primary Market Areas . .16 |
| | Outlook . .20 |
| | Methamphetamine . .21 |
| | Introduction and Trends .21 |
| | Availability . .22 |
| | Demand .23 |
| | Production .23 |
| | Transportation . .23 |
| | Distribution . .24 |
| | Availability .24 |
| | Demand. .27 |
| | Predominant User Groups .27 |
| | Trends in Use .29 |
| | Perceptions of Use .29 |
| | Trends in Consequences of Use .30 |
| | Production. .30 |
| | Domestic Production .31 |
| | Foreign Production . .33 |
| | Precursor Chemicals .34 |
| | Transportation 35 |
| | Routes From Foreign Source Areas . 35 |
| | Routes from Domestic Source Areas 37 |
| | Distribution 37 |
| | Primary Market Areas 37 |
| | Outlook . 40 |
| | Marijuana . 41 |
| | Introduction and Trends. 41 |
| | Availability 42 |
| | Demand . 43 |
| | Production . 43 |
| | Transportation 44 |
| | Distribution 44 |
| | Availability 45 |
| | Demand . 47 |
| | Predominant User Groups . 47 |
| | Trends in Use 48 |
| | Perceptions of Use 49 |
| | Trends in Consequences of Use 49 |
| | Production . 50 |
| | Domestic Production . 50 |
| | Foreign Production 52 |
| | Transportation 54 |
| | To the United States . 54 |
| | In the United States 57 |
| | Distribution 58 |
| | Primary Market Areas 59 |
| | Outlook . 63 |
| | Heroin 65 |
| | Introduction and Trends. 65 |
| | Availability 66 |
| | Demand . 67 |
| | Production . 67 |
| | Transportation 67 |
| | Distribution 68 |
| | Availability 68 |
| | Demand . 70 |
| | Predominant User Groups . 70 |
| | Trends in Use 71 |
| | Perceptions of Use 71 |
| | Trends in Consequences of Use 72 |
| | Production . 73 |
| | Transportation 75 |
| | Distribution 78 |
| | Primary Market Areas 80 |
| | Outlook . 82 |
| | MDMA. .83 |
| | Introduction and Trends .83 |
| | Availability . .84 |
| | Demand .84 |
| | Production .84 |
| | Transportation . .85 |
| | Distribution . .85 |
| | Availability .85 |
| | Demand. .87 |
| | Predominant User Groups .87 |
| | Trends in Use . .88 |
| | Perceptions of Use .88 |
| | Trends in Consequences of Use .89 |
| | Production. .89 |
| | Foreign Sources .89 |
| | Domestic Sources .90 |
| | Transportation.91 |
| | Foreign Routes . .92 |
| | Distribution .94 |
| | Primary Market Areas . .96 |
| | Outlook . .98 |
| | Pharmaceuticals . .99 |
| | Introduction.99 |
| | Demand.100 |
| | Trends in Abuse . .100 |
| | Consequences of Abuse . .101 |
| | Availability .102 |
| | Pharmaceutical Diversion and Distribution .102 |
| | Doctor Shopping .103 |
| | Prescription Fraud . .104 |
| | Unscrupulous Physicians .104 |
| | Pharmaceutical Theft . .104 |
| | Internet . .105 |
| | Outlook .107 |
| | Other Dangerous Drugs .109 |
| | Introduction. .109 |
| | GHB .109 |
| | Availability .110 |
| | Demand . .110 |
| | Production . .112 |
| | Transportation and Distribution . .112 |
| | Outlook . .112 |
| | Ketamine. .113 |
| | Availability .113 |
| | Demand . .113 |
| | Production . .114 |
| | Transportation and Distribution . 114 |
| | Outlook 115 |
| | LSD . 115 |
| | Availability . 115 |
| | Demand 116 |
| | Production 117 |
| | Transportation and Distribution . 117 |
| | Outlook 118 |
| | PCP . 118 |
| | Availability . 118 |
| | Demand 119 |
| | Production 120 |